{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Girard A"],"funding":["Joseph C. Edwards","Canada Research Chair on Women’s Cardiac Valvular Health","Medical Research Council","Canadian Institutes of Health","Quebec Heart and Lung Institute"],"pagination":["oead032"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10108885"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["3(2)"],"pubmed_abstract":["<h4>Aims</h4>Elevated lipoprotein(a) [Lp(a)] levels are associated with the risk of coronary artery disease (CAD) and calcific aortic valve stenosis (CAVS). Observational studies revealed that Lp(a) and C-reactive protein (CRP) levels, a biomarker of systemic inflammation, may jointly predict CAD risk. Whether Lp(a) and CRP levels also jointly predict CAVS incidence and progression is unknown.<h4>Methods and results</h4>We investigated the association of Lp(a) with CAVS according to CRP levels in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk study (<i>n</i> = 18 226, 406 incident cases) and the UK Biobank (<i>n</i> = 438 260, 4582 incident cases), as well as in the ASTRONOMER study (<i>n</i> = 220), which assessed the haemodynamic progression rate of pre-e"],"journal":["European heart journal open"],"pubmed_title":["Impact of C-reactive protein levels on lipoprotein(a)-associated aortic stenosis incidence and progression."],"pmcid":["PMC10108885"],"funding_grant_id":["MC_UU_00006/1"],"pubmed_authors":["Boekholdt SM","Puri R","Mathieu P","Gaillard E","Theriault S","Paulin A","Dumesnil J","Capoulade R","Stroes ESG","Chan KL","Tam JW","Clavel MA","Pibarot P","Girard A","Tsimikas S","Wareham NJ","Teo KK","Couture C","Arsenault BJ","Manikpurage HD"],"additional_accession":[]},"is_claimable":false,"name":"Impact of C-reactive protein levels on lipoprotein(a)-associated aortic stenosis incidence and progression.","description":"<h4>Aims</h4>Elevated lipoprotein(a) [Lp(a)] levels are associated with the risk of coronary artery disease (CAD) and calcific aortic valve stenosis (CAVS). Observational studies revealed that Lp(a) and C-reactive protein (CRP) levels, a biomarker of systemic inflammation, may jointly predict CAD risk. Whether Lp(a) and CRP levels also jointly predict CAVS incidence and progression is unknown.<h4>Methods and results</h4>We investigated the association of Lp(a) with CAVS according to CRP levels in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk study (<i>n</i> = 18 226, 406 incident cases) and the UK Biobank (<i>n</i> = 438 260, 4582 incident cases), as well as in the ASTRONOMER study (<i>n</i> = 220), which assessed the haemodynamic progression rate of pre-e","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2026-05-28T08:06:27.354Z","creation":"2024-11-20T15:16:49.27Z"},"accession":"S-EPMC10108885","cross_references":{"pubmed":["37077580"],"doi":["10.1093/ehjopen/oead032"]}}